Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer.

UNLABELLED: ISA-2011B is a phosphatidylinositol-4-phosphate 5-kinase-α (PIP5K1α) inhibitor that has been reported to be selective in suppressing the growth of prostate, breast and hepatic cancer cells. Here, cell viability of 2-dimensional (2D) cultures and 3-dimensional (3D) spheroids of four colorectal cancer (CRC) cell lines with different mutations were evaluated after treatment with the drug ISA-2011B.

METHODS

The CRC cell lines were investigated for viability in 2D and 3D spheroid cultures. The 3D spheroids were subjected to imaging, and the average volumes were measured.

RESULTS

The results show different treatment effects of ISA-2011B on the four CRC cell lines, indicating that mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol 3-kinase (PI3K) genes can play a role in the outcome of treatment.

CONCLUSIONS

With additional studies, we suggest that ISA-2011B can be a promising drug target in CRC.